Christensen K
Scand J Rheumatol. 1986;15(1):80-4. doi: 10.3109/03009748609092673.
Twenty-eight patients with active classical or definite rheumatoid arthritis were randomly allocated to treatment with fenflumizole 200 mg or 100 mg or placebo daily in a 2-week double-blind placebo-controlled study. Three patients dropped out and 25 patients completed the study. Ten patients received fenflumizole 100 mg daily, 7 patients received fenflumizole 200 mg daily and 8 patients received placebo. Clinical and laboratory assessments before and during the study revealed that in patients treated with fenflumizole, grip strength, morning stiffness and walking time improved significantly. No improvement could be seen in the placebo group. No side effects attributable to fenflumizole were observed during the study.
在一项为期2周的双盲安慰剂对照研究中，28例活动期典型或确诊类风湿性关节炎患者被随机分配，分别每日服用200毫克或100毫克芬氟米唑或安慰剂。3例患者退出研究，25例患者完成了研究。10例患者每日服用100毫克芬氟米唑，7例患者每日服用200毫克芬氟米唑，8例患者服用安慰剂。研究前和研究期间的临床及实验室评估显示，服用芬氟米唑治疗的患者握力、晨僵和步行时间均有显著改善。安慰剂组未见改善。研究期间未观察到归因于芬氟米唑的副作用。
